Smits Anja, Jakola Asgeir S
Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg, Sweden; Department of Neuroscience, Section of Neurology, Uppsala University, 751 85 Uppsala, Sweden.
Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg, Sweden; Department of Neurosurgery, Sahlgrenska University Hospital, Blå Stråket 5, 41345 Gothenburg, Sweden; Department of Neurosurgery, St Olavs Hospital, Prinsesse Kristinas gate 3, 7030 Trondheim, Norway.
Neurosurg Clin N Am. 2019 Jan;30(1):35-42. doi: 10.1016/j.nec.2018.08.002. Epub 2018 Nov 1.
Diffuse low-grade gliomas (DLGGs) are primary brain tumors characterized by slow growth but extensive infiltration into the surrounding brain. Patients are typically 30 to 40 years at disease onset and present with focal or focal to bilateral tonic-clonic seizures. The tumor will transform into a malignant glioma and eventually lead to death, but after varying lengths of time. The specific features of DLGG impose a major challenge to decide optimal treatment strategies and timing of treatment, while maintaining patients' quality of life. We discuss the clinical challenges at disease onset with regard to the natural history and long-term prognosis.
弥漫性低级别胶质瘤（DLGGs）是原发性脑肿瘤，其特点是生长缓慢，但会广泛浸润周围脑组织。患者发病时通常为30至40岁，表现为局灶性或从局灶性发展为双侧强直阵挛性癫痫发作。肿瘤会转变为恶性胶质瘤并最终导致死亡，但时间长短不一。DLGG的具体特征给确定最佳治疗策略和治疗时机带来了重大挑战，同时还要维持患者的生活质量。我们讨论疾病初发时在自然病史和长期预后方面的临床挑战。
